Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus

Experimental Eye Research

Volumn 121, Issue , 2014, Pages 121-129

  Elsaid, Naba ^a   Somavarapu, Satyanarayana ^a   Jackson, Timothy L ^b,c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Cholesterol poly(ethylene) glycol; Micelle; Permeation; Rapamycin; Sclera; Sirolimus

Indexed keywords

CHOLESTEROL POLY(ETHYLENE) GLYCOL NANOCARRIER; NANOCARRIER; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CRITICAL MICELLE CONCENTRATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG PENETRATION; DRUG RETENTION; DRUG SCREENING; DRUG SYNTHESIS; EYE DISEASE; IMMUNOGENICITY; LASER DOPPLER FLOWMETRY; LIGHT SCATTERING; MELTING POINT; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCLERA; SURFACE CHARGE; TISSUE PREPARATION; TRANSMISSION ELECTRON MICROSCOPY; TRANSSCLERAL DELIVERY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

AGE-RELATED MACULAR DEGENERATION; CHOLESTEROL POLY(ETHYLENE) GLYCOL; MICELLE; PERMEATION; RAPAMYCIN; SCLERA; SIROLIMUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DRUG CARRIERS; DRUG STABILITY; MICELLES; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; POWDER DIFFRACTION; SCLERA; SIROLIMUS; SWINE;

EID: 84895961950     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.02.001     Document Type: Article

References (62)

1. Aliabadi H.M., Shahin M., Brocks D.R., Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin. Pharmacokinet. 2008, 47:619-634.
2. Amrite A.C., Kompella U.B. Nanoparticles and microparticles: particle engineering, cell uptake, invivo disposition & efficacy. Drug Deliv. Technol. 2007, 7:52-56.
3. Anderson O.A., Jackson T.L., Singh J.K., Hussain A.A., Marshall J. Human transscleral albumin permeability and the effect of topographical location and donor age. Investig. Ophthalmol. Vis. Sci. 2008, 49:4041-4045.
4. Araújo J., Garcia M.L., Mallandrich M., Souto E.B., Calpena A.C. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): invitro and exvivo studies. Nanomedicine 2012, 8:1034-1041.
5. Baldursdottir S., Tian F., Santacruz B.G., Jørgensen A.C., Rantanen J. The influence of thermal history on the physical behaviour of poly(ethylene glycol) (PEG). Pharm. Dev. Technol. 2012, 17:195-203.
6. Buckley C.P., Kovacs A.J. Melting behaviour of low molecular weight poly (ethylene-oxide) fractions 2. Folded chain crystals. Colloid Polym. Sci. 1976, 254:695-715.
7. Buech G., Bertelmann E., Pleyer U., Siebenbrodt I., Borchert H.H. Formulation of sirolimus eye drops and corneal permeation studies. J.Ocul. Pharmacol. Ther. 2007, 23:292-303.
8. Casettari L., Vllasaliub D., Castagninoa E., Stolnikb S., Howdlec S., Illum L. PEGylated chitosan derivatives: synthesis, characterizations and pharmaceutical applications. Prog. Polym. Sci. 2012, 37:659-685.
9. Cheruvu N.P., Kompella U.B. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Investig. Ophthalmol. Vis. Sci. 2006 Oct, 47(10):4513-4522.
10. Conquet Ph, Durand G., Laillier J., Plazonnet B. Evaluation of ocular irritation in the rabbit: objective versus subjective assessment. Toxicol. Appl. Pharmacol. 1977, 39:129-139.
11. Cooper, E.R., Kleinman, D.M., Nivaggioli, T., Dor, P.J.M., Mudumba, S., 2012. Transscleral Delivery. U.S. Pat. 20120034279.
12. Craig D.Q.M., Newton J.M. Characterisation of polyethylene glycols using differential scanning calorimetry. Int. J. Pharm. 1991, 74:33-41.
13. Cruysberg L.P., Nuijts R.M., Geroski D.H., Koole L.H., Hendrikse F., Edelhauser H.F. Invitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J.Ocul. Pharmacol. Ther. 2002 Dec, 18(6):559-569.
14. Cruysberg L.P., Franklin A.J., Sanders J., Self C., Yuan P., Csaky K.G., Robinson M.R., Kohn E.C., Edelhauser H.F. Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2). Retina 2005 Dec, 25(8):1022-1031.
15. De Campos A.M., Sánchez A., Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporine A. Int. J. Pharm. 2001, 224:159-168.
16. Elsaid N., Jackson T.L., Gunic M., Somavarapu S. Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin. Investig. Ophthalmol. Vis. Sci. 2012, 53:8105-8111.
17. Felt O., Furrer P., Mayer J.M., Plazonnet B., Buri P., Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int. J. Pharm. 1999, 180:185-193.
18. Forrest M.L., Won C.Y., Malick A.W., Kwon G.S. Invitro release of the mTOR inhibitor sirolimus from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J.Control Release 2006, 110:370-377.
19. Geroski D.H., Edelhauser H.F. Transscleral drug delivery for posterior segment disease. Adv. Drug. Deliv. Rev. 2001 Oct 31, 52(1):37-48.
20. Guba M., von Breitenbuch P., Steinbauer M., et al. Sirolimus inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
21. Hathout R.M., Mansour S., Mortada N.D., Guinedi A.S. Liposomes as an ocular delivery system for acetazolamide: invitro and invivo studies. AAPS PharmSciTech 2007, 8:1.
22. Hillenkamp J., Hussain A.A., Jackson T.L., Cunningham J.R., Marshall J. The influence of path length and matrix components on ageing characteristics of transport between the choroid and the outer retina. Investig. Ophthalmol. Vis. Sci. 2004, 45:1493-1498.
23. Hillenkamp J., Hussain A.A., Jackson T.L., Cunningham J.R., Marshall J. Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina. Investig. Ophthalmol. Vis. Sci. 2004, 45:4529-4534.
24. Houchens D.P., Ovejera A.A., Riblet S.M., Slagel D.E. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur. J. Cancer Clin. Oncol. 1983, 19:799-805.
25. Jackson T.L., Hussain A., Hodgetts A., Morley A.M., Hillenkamp J., Sullivan P.M., Marshall J. Human scleral hydraulic conductivity: age-related changes, topographical variation, and potential scleral outflow facility. Investig. Ophthalmol. Vis. Sci. 2006, 47:4942-4946.
26. Kalyanasundaram K., Thomas J.K. Environmental effects on vibronic band intensities in pyrene monomer fluorescence and their application in studies of micellar systems. J.Am. Chem. Soc. 1977, 99:2039-2044.
27. Kao J.C., Geroski D.H., Edelhauser H.F. Transscleral permeability of fluorescent-labelled antibiotics. J.Ocul. Pharmacol. Ther. 2005 Feb, 21(1):1-10.
28. Kim J.H., Kim K.W., Kim M.H., Yu Y.S. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology 2009, 20:505101.
29. Kim M.S., Kim J.S., Park H.J., Cho W.K., Cha K.H., Hwang S.J. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int. J. Nanomed. 2011, 6:2997-3009.
30. Kundaiker S., Hussain A.A., Marshall J. Component characteristics of the vectorial transport system for taurine in isolated bovine retinal pigment epithelium. J.Physiol. 1996, 492:505-516.
31. Kwon, G.S., Forrest, M.L., Wisconsin Alumni Research Foundation, 2006. Micelle Composition of Polymer and Passenger Drug. US Patent No. 20060251710.
32. Lasic D.D. Liposomes: from Physics to Applications 1993, Elsevier, USA.
33. Li J., Wu L., Wu W., Wang B., Wang Z., Xin H., Xu Q. Apotential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. Int. J. Pharm. 2013 Oct 15, 455(1-2):75-84.
34. Lin W.J., Juang L.W., Lin C.C. Stability and release performance of a series of PEGylated copolymeric micelles. Pharm. Res. 2003, 20:668-673.
35. Lu W., Li F., Mahato R.I. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) nanocarriers for sirolimus delivery: invitro characterization and biodistribution. J.Pharm. Sci. 2011, 100:2418-2429.
36. Luangtana-Anan M., Limmatvapirat S., Nunthanid J., Chalongsuk R., Yamamoto K. Polyethylene glycol on stability of chitosan microparticulate carrier for protein. AAPS PharmSciTech 2010, 11:1376-1382.
37. Marques H.M.C., Hadgraft J., Kellaway I.W. Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int. J. Pharm. 1990, 63:259-266.
38. Martel R.R., Klicius J., Galet S. Inhibition of the immune response by sirolimus, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 1977, 55:48-51.
39. Melo R.C., Sabban A., Weller P.F. Leukocyte lipid bodies: inflammation-related organelles are rapidly detected by wet scanning electron microscopy. J.Lipid Res. 2006, 47:2589-2594.
40. Mitra, A.K., Velagaleti, P.R., Grau, U.M., Lux Bioscience Inc., 2010. Topical Drug Delivery Systems for Ophthalmic Use. US Patent. No. 20100310642.
41. Morand K., Bartoletti A.C., Bochot A., Barratt G., Brandely M.L., Chast F. Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. Int. J. Pharm. 2007, 344:150-153.
42. Nagarwal R.C., Kant S., Singh P.N., Maiti P., Pandit J.K. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J.Control Release 2009, 136:2-13.
43. Nakanishi M., Patil R., Ren Y., Shyam R., Wong P., Mao H.Q. Enhanced stability and knockdown efficiency of poly(ethylene glycol)-b-polyphosphoramidate/siRNA micellar nanoparticles by co-condensation with sodium triphosphate. Pharm. Res. 2011, 28:1723-1732.
44. Nicoli S., Ferrari G., Quarta M., et al. Porcine sclera as a model of human sclera for invitro transport experiments: histology, SEM, and comparative permeability. Mol. Vis. 2009, 15:259-266.
45. Olsen T.W., Sanderson S., Feng X., Hubbard W.C. Porcine sclera: thickness and surface area. Investig. Ophthalmol. Vis. Sci. 2002, 43:2529-2532.
46. Pade V., Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res. 1997, 14:1210-1215.
47. Preethama A.C., Satisha C.S. Formulation of a poorly water-soluble drug sirolimus in solid dispersions to improve dissolution. J.Dispers. Sci. Technol. 2011, 32:778-783.
48. Prego C., Torres D., Fernandez-Megia E., Novoa-Carballal R., Quiñoá E., Alonso M.J. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J.Control Release 2006, 111:299-308.
49. Rabinovich-Guilatt L., Couvreur P., Lambert G., Dubernet C. Cationic vectors in ocular drug delivery. J.Drug Target. 2004, 12:623-633.
50. Ribeiro A., Sosnik A., Chiappetta D.A., Veiga F., Concheiro A., Alvarez-Lorenzo C. Single and mixed poloxamine nanocarriers as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy. J.R. Soc. Interface 2012, 9:2059-2069.
51. Ricciutelli M., Di Martino P., Barboni L., Martelli S. Evaluation of sirolimus chemical stability in volatile-organic solvents by HPLC. J.Pharm. Biomed. Anal. 2006, 41:1070-1074.
52. Rouf M.A., Vural I., Bilensoy E., Hincal A., Erol D.D. Sirolimus-cyclodextrin complexation: improved solubility and dissolution rate. J.Incl. Phenom. Macrocycl. Chem. 2011, 70:167-175.
53. Sharma K., Somavarapu S., Colombani A., Govind N., Taylor K.M. Cross-linked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers. Eur. J. Pharm. Biopharm. 2012 May, 81(1):74-81.
54. Simamora P., Alvarez J.M., Yalkowsky S.H. Solubilization of sirolimus. Int. J. Pharm. 2001, 213:25-29.
55. Slager T.L., Prozonic F.M. Simple methods for calibrating IR in TGA/IR analyses. Thermochim. Acta 2005, 426:93-99.
56. Srikantha N., Mourad F., Suhling K., et al. Influence of molecular shape, conformability, net surface charge, and tissue interaction on transscleral macromolecular diffusion. Exp. Eye Res. 2012, 102:85-92.
57. Swindells D.C.N., White P.S., Findlay J.A. The X-ray crystal structure of sirolimus, C51H79NO13. Can. J. Chem. 1978, 56:2491-2492.
58. Tang B., Yang Z., Zhang S. Poly(polyethylene glycol methyl ether methacrylate) as novel solid-solid phase change material for thermal energy storage. J.Appl.Polym. Sci. 2012, 125:1377-1381.
59. Vega E., Gamisans F., García M.L., Chauvet A., Lacoulonche F., Egea M.A. PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J.Pharm. Sci. 2008, 97:5306-5317.
60. Wei Z., Hao J., Yuan S., Li Y., Juan W., Sha X., Fang X. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and invitro characterization. Int. J. Pharm. 2009, 376:176-185.
61. Yáñez J.A., Forrest M.L., Ohgami Y., Kwon G.S., Davies N.M. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) nanocarriers of sirolimus. Cancer Chemother. Pharmacol. 2008, 61:133-144.
62. Zhang X., Jacksona J.K., Burt H.M. Development of amphiphilic diblockcopolymers as micellar carriers of taxol. Int. J. Pharm. 1996, 132:195-206.